

Essential Molecular Determinants for Thyroid Hormone Transport and First Structural Implications for Monocarboxylate Transporter 8^{*[S]}

Received for publication, April 1, 2010, and in revised form, June 18, 2010 Published, JBC Papers in Press, July 13, 2010, DOI 10.1074/jbc.M110.129577

Anita Kinne⁺¹, Gunnar Kleinau^{S¶1}, Carolin S. Hoefig[‡], Annette Grüters^S, Josef Köhrle[‡], Gerd Krause[¶], and Ulrich Schweizer⁺²

From the [‡]Institut für Experimentelle Endokrinologie and ^SInstitut für Experimentelle Pädiatrische Endokrinologie, Charité-Universitätsmedizin Berlin, 13353 Berlin and the [¶]Leibniz-Institut für Molekulare Pharmakologie, 13125 Berlin, Germany

Monocarboxylate transporter 8 (MCT8, SLC16A2) is a thyroid hormone (TH) transmembrane transport protein mutated in Allan-Herndon-Dudley syndrome, a severe X-linked psychomotor retardation. The neurological and endocrine phenotypes of patients deficient in MCT8 function underscore the physiological significance of carrier-mediated TH transmembrane transport. MCT8 belongs to the major facilitator superfamily of 12 transmembrane-spanning proteins and mediates energy-independent bidirectional transport of iodothyronines across the plasma membrane. Structural information is lacking for all TH transmembrane transporters. To gain insight into structure-function relations in TH transport, we chose human MCT8 as a paradigm. We systematically performed conventional and liquid chromatography-tandem mass spectrometry-based uptake measurements into MCT8-transfected cells using a large number of compounds structurally related to iodothyronines. We found that human MCT8 is specific for L-iodothyronines and requires at least one iodine atom per aromatic ring. Neither thyronamines, decarboxylated metabolites of iodothyronines, nor triiodothyroacetic acid and tetraiodothyroacetic acid, TH derivatives lacking both chiral center and amino group, are substrates for MCT8. The polyphenolic flavonoids naringenin and F21388, potent competitors for TH binding at transthyretin, did not inhibit T₃ transport, suggesting that MCT8 can discriminate its ligand better than transthyretin. Bioinformatic studies and a first molecular homology model of MCT8 suggested amino acids potentially involved in substrate interaction. Indeed, alanine mutation of either Arg⁴⁴⁵ (helix 8) or Asp⁴⁹⁸ (helix 10) abrogated T₃ transport activity of MCT8, supporting their predicted role in substrate recognition. The MCT8 model allows us to rationalize potential interactions of amino acids including those mutated in patients with Allan-Herndon-Dudley syndrome.

Thyroid hormones (TH)³ are amino acid derivatives. Because of their zwitterionic nature, TH and their derivatives require transmembrane transporters to mediate their translocation across the plasma membrane (1). Several classes of transmembrane transporter proteins of the major facilitator superfamily (MFS) are capable of TH transport; organic anion transporters two and three (Oatp2 and Oatp3) were the first TH transporters cloned (2). Later, L-type amino acid transporters (Lat1, Lat2) (3) and monocarboxylate transporters eight and ten (MCT8 and MCT10) were shown to transport TH (4, 5). Among these transporters, only MCT8 is specific for TH. Mutations in MCT8/SLC16A2 lead to severe psychomotor retardation and TH abnormalities in humans (6, 7), including the Allan-Herndon-Dudley Syndrome (8). Patients suffering from mutations in MCT8 are characterized by high serum T₃ values associated with low T₄ and inappropriately normal thyroid-stimulating hormone. This clinical phenotype suggested that MCT8 is involved in pituitary feedback control of the TH axis. Sensitivity to TH thus depends on the expression of TH transporter molecules. Expression of MCT8 in the mouse brain (9) supported the idea that TH import into neurons may be affected in patients afflicted with the Allan-Herndon-Dudley syndrome. Mice deficient in MCT8 recapitulate the disturbed serum thyroid hormone parameters (10, 11) but exhibit only mild neurological abnormalities (12). Murine neurons are apparently protected from the lack of MCT8 by expression of alternative T₃ transporters such as Lat2, which is not present in human developing neurons (12).

More than two dozen mutations in MCT8 have been identified in human patients (13). Genotype-phenotype correlations suggested that most missense mutations cause a complete loss-of-function phenotype in patients. A comparison of 12 missense mutants revealed that pathogenic MCT8 mutations may affect expression, surface translocation, or specifically the substrate transport mechanism (14). Possibly, homodimerization may also play a role that we currently do not understand (15, 16). To our knowledge, no data are yet available relating structural features and transport mechanism of MCT8.

^{*} This work was supported by grants from Deutsche Forschungsgemeinschaft (DFG) Project SFB665 TP A7-2, Charité, and EnForCé.

^[S] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental Figs. S1 and S2.

¹ Both authors contributed equally to this work.

² To whom correspondence should be addressed: Institut für Experimentelle Endokrinologie, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. Tel.: 49-30450524080; Fax: 49-30-450-524-922; E-mail: ulrich.schweizer@charite.de.

³ The abbreviations used are: TH, thyroid hormone; GlpT, glycerol-3-phosphate transporter; ICL, intracellular loop; MCT8, monocarboxylate transporter 8; MDCK, Madin-Darby canine kidney; MFS, major facilitator superfamily; PDB, protein data bank; T₃, 3,3',5-triiodo-L-thyronine; T₄, 3,3',5,5'-tetraiodo-L-thyronine, thyroxine; TAM, thyronamines; TMH, transmembrane helix; TRIAC, 3,3',5-triiodo-thyroacetic acid; 3-T₁AM, 3-iodothyronamine.

Our goal in this study was to obtain new functional and structural insights in the complex system of substrate binding and transport. Systematic analysis of substrate molecules for MCT8-mediated cellular uptake revealed several structural determinants for substrate recognition by MCT8: an L-amino acid side chain and at least an iodine substitution in the three positions of both aromatic rings of the thyronine moiety. We also designed a homology model of human MCT8 to identify amino acids potentially involved in substrate recognition. Strikingly, mutations of charged amino acids predicted to interact with substrate disrupted T_3 import into cells. Thus, functional data support the first predictions from our structural MCT8 model.

EXPERIMENTAL PROCEDURES

Site-directed Mutagenesis and Stable Cell Lines—Mutations were introduced into human MCT8 by overlap extension PCR with the following primers (mutated bases in boldface): R445A, forward, 5'-CAGGCCTTGGGGCTCTTGTGTCAGGC-CAC-3' and R445A, reverse, 5'-GTGGCCTGACACAAGAG-CCCCAAGGCCTG-3'; and D498A, forward, 5'-CTGGGCC-TTTGCGCCGGCTTCTTCATCAC-3' and D498A, reverse 5'-GTGATGAAGAAGCCGGCGCAAAGGCCAG-3'. Plasmids were stably transfected into MDCK1 cells as described previously (14).

T_3 Uptake Assays—One day before the experiments, 200,000 cells/well were seeded into 12-well plates. [125 I] T_3 (PerkinElmer Life Sciences) was purified from iodide ions by adsorption chromatography and finally resuspended in DMEM-F12 (1:1) without serum (14). For competitive inhibition studies, cells were exposed to 10 nM [125 I] T_3 tracer in medium for 3 min in the presence or not of 10 μ M of test compound (1 mM for aromatic amino acids and bromsulphthalein), medium was removed, and radioactivity associated with the cells was determined (supplemental Fig. S2). Iodothyronines and related compounds were first dissolved in dimethyl sulfoxide (DMSO) (1000-fold final concentration) and then in medium. Aromatic amino acids were dissolved in uptake buffer (125 mM NaCl, 5 mM KCl, 1.3 mM $CaCl_2$, 1.2 mM $MgCl_2$, 25 mM HEPES, 5.6 mM glucose, pH 7.4). For time course assays, stably transfected cell lines were incubated with 10 nM tracer for 1–30 min. After a single wash with ice-cold PBS, cells were lysed in 40 mM NaOH, and radioactivity of the lysate was measured in a gamma counter (Wizard, PerkinElmer Life Sciences). Each experiment was performed on at least two different days with different batches of cells in triplicate. Radioactivity associated with empty vector-transfected cells was subtracted as background, and the activity associated with the wild-type MCT8 clone without inhibitor was defined as 100%.

For determination of apparent K_m values of wild-type MCT8, MDCK1 cells were incubated for 3 min with T_3 at concentrations ranging from 500 nM to 12 μ M containing or not [125 I] T_3 as tracer. A Michaelis-Menten transport mechanism was assumed for calculations (GraphPad 4.0). Iodothyronines were supplied by Formula GmbH (Berlin, Germany), thyronamines were kindly provided by Dr. Thomas Scanlan (Portland, OR), and was provided by F21388 by Prof. Schreier (Würzburg, Germany). TRIAC and 3,3',5,5'-tetraiodo-thyroacetic acid were

TABLE 1

Device-specific LC-MS/MS parameters

| Compound | (<i>m/z</i>) ^a Q1 ^b | (<i>m/z</i>) Q3 ^c | DP ^d | CE ^e | CXP ^f |
|--------------------|---|--------------------------------|-----------------|-----------------|------------------|
| T_3 | 651.8 | 605.7 | 116.0 | 29.0 | 18.0 |
| T_3 AM | 607.8 | 479.0 | 116.0 | 51.0 | 24.0 |
| | | 210.1 | 116.0 | 61.0 | 16.0 |
| TRIAC | 620.8 | 126.8 | –15.0 | –58.0 | –5.0 |
| 3- T_1 AM- d_4 | 360.0 | 343.1 | 86.0 | 21.0 | 10.0 |
| | | 216.1 | 86.0 | 29.0 | 34.0 |

^a (*m/z*), mass to charge ratio.

^b (*m/z*), Q1, *m/z* of parent ion in first quadrupole.

^c (*m/z*), Q3, *m/z* of most intensive product ion in third quadrupole.

^d DP, declustering potential (V).

^e CE, collision energy (V).

^f CXP, collision cell exit potential (V).

obtained from Henning (Berlin, Germany), and naringenin was purchased from Sigma-Aldrich (Taufkirchen, Germany).

The uptake of T_3 , T_3 AM, and TRIAC by wild-type MCT8 and the mutants R445A and D498A was directly measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (17, 18). The cells were incubated for 3 min in DMEM-F12 (1:1) with a final concentration of 50 μ M. Then the medium was removed, and the cells were washed once with ice-cold PBS and harvested.

LC-MS/MS Instrumentation and Detection—LC-MS/MS analyses were performed using a Shimadzu UFLC system (Shimadzu Scientific Instruments, Columbia, MD) and a 4000QTRAP triple-quadrupole tandem mass spectrometer (Applied Biosystems, Darmstadt, Germany) equipped with TurboIonSpray interface. The chromatographic column and the autosampler were operated at 40 and 10 °C, respectively. The detection was performed using positive electrospray ionization for T_3 and T_3 AM and negative electrospray ionization for TRIAC in the selected reaction monitoring mode. The mass spectrometric working parameters were: TurboIon spray voltage (internal standard), 5500 V; curtain gas (CUR), 30 p.s.i.; collision gas (CAD), 5 p.s.i.; nebulizer gas (GS1), 60 p.s.i.; heater gas (GS2), 50 p.s.i.; entrance potential, 10 V; source temperature, 400 °C; dwell time, 90 ms.

Chromatographic separation of all substances was achieved using a Synergi Polar-RP 80-Å column (150 × 2 mm; Phenomenex, Aschaffenburg, Germany) and an analytical Guard Cartridge System (4.0 × 2.0 mm, Phenomenex) using a gradient elution program at a flow rate of 300 μ l/min. Simultaneous detection of all substances in the same biological sample was performed using a modified LC-MS/MS method as described before (18). With the 4000QTRAP triple-quadrupole tandem mass spectrometer, we reduced the time per run to 25 min using a gradient elution program: mobile phase A (water/acetonitrile/acetic acid, 95:5:0.6), 0–2 min, 2% B; 2–12 min, 40% B; 12–15 min, 60% B; 15–15.5 min, 90% B; 15.5–16.5 min, 90% B; 16.5–17 min, 2% B; 17–19.95 min, 2% B. The device-specific mass spectrometric parameters for analytes are presented in Table 1. Data processing was performed using Bio Analyst version 1.5. software (Applied Biosystems). Liquid-liquid extraction of all compounds for LC-MS/MS analysis was performed as described previously (17). For LC-MS/MS analysis, 4 pmol of deuterated 3- T_1 AM- d_4 was used as internal standard.

80 μg of total cellular protein fraction) were separated on SDS gels, transferred onto nitrocellulose membranes, and probed with an MCT8 antibody (Atlas, Stockholm, Sweden). An anti-



body directed against β -actin (Rockland, Gilbertsville, PA) was used for loading control. Every experiment was performed at least twice with similar results.

Bioinformatics and Molecular Homology Modeling—All amino acid sequence alignments (Fig. 1 and supplemental Fig. S1) were produced using a combination of automatic and manual procedures. For automatic alignments, ClustalW (19) software was applied with the Blossum62 amino acid similarity matrix. Few manual refinements were performed including Gap-introduction at loop regions, but not in transmembrane helices. Alignments were produced with the BioEdit software package.

Human MCT family members were aligned to analyze shared and divergent features in amino acid composition (Fig. 1). The potential dimensions of transmembrane helices (TMH) were predicted based on observable helices in the crystal structure of the glycerol-3-phosphate transporter (GlpT, PDB code 1PW4 (20)), another member of the MFS superfamily (supplemental Fig. S1), which can be used as a structural template for homology models (see section below). From this alignment, it becomes obvious that MCT family proteins share high sequence and most likely structural similarity, despite some regions of flexibility like the third intracellular loop (ICL3).

The high sequence similarity among MCT proteins suggested to us to propose a unifying numbering system for this protein subfamily. The rationale of this numbering scheme is adopted from the description by Ballesteros and Weinstein (21) for family A G-protein-coupled receptors. We use the numbering convention $x.50$ for the most conserved amino acids in each TMH x . For example, the most highly conserved residue in TMH1 is defined as 1.50, and in TMH2, it is defined as 2.50, etc. We suggest the following amino acids as highly conserved for all MCT (Fig. 1): Trp^{1.50} (MCT8 Trp¹⁷⁵) at TMH1, TMH2 Pro^{2.50} (MCT8 Pro²³³), TMH3 Gly^{3.50} (MCT8 Gly²⁵⁸), TMH4 Gly^{4.50} (MCT8 Gly²⁷⁶), TMH5 Gly^{5.50} (MCT8 Gly³¹²), TMH6 Gly^{6.50} (MCT8 Ser³⁵¹), TMH7 Pro^{7.50} (MCT8 Pro⁴¹²), TMH8 Arg^{8.50} (MCT8 Arg⁴⁴⁵), TMH9 Gly^{9.50} (MCT8 Gly⁴⁷²), TMH10 Gly^{10.50} (MCT8 Gly⁴⁹⁹), TMH11 Pro^{11.50} (MCT8 Pro⁵³⁶), TMH12 Phe(Tyr)^{12.50} (MCT8 Phe⁵⁵⁴).

The crystal structure of the inward facing conformation of GlpT from *Escherichia coli* was used as a structural template for an MCT8 homology model (20). The alignment between human MCT8 and GlpT amino acid sequences reveals a similarity score of 25.5% (supplemental Fig. S1). With small deviations, the helix dimensions observed in the GlpT crystal structure are applicable for human MCT8. The reliability of this structural template is supported by examples of modeling for other members of the MFS-like GLUT1 (22) or MCT1 (23, 24).

Helices in MCT8 comprise the following residues: TMH1, Phe¹⁶⁶–Leu²⁰²; TMH2, Gln²¹²–Thr²³⁹; TMH3, Cys²⁴⁴–His²⁶⁰; TMH4, Arg²⁷¹–His²⁹⁶; TMH5, Gln²⁹⁹–Met³²⁶; TMH6, Thr³³⁶–Thr³⁵³; TMH7, Gly⁴⁰¹–Glu⁴²⁹; TMH8, Val⁴³⁵–Leu⁴⁵⁸; TMH9, Ile⁴⁶¹–Met⁴⁷⁷; TMH10, Phe⁴⁸⁴–Leu⁵¹²; TMH11, Ala⁵²¹–Gly⁵⁴⁸; and TMH12, Ala⁵⁵³–Asp⁵⁸⁹.

Gaps of missing residues in the loops of the template structure were closed by the Loop Search tool implemented in Sybyl 7.35 (Tripos Inc., St. Louis, MO). Comparison with loop conformations extracted from the PDB by the SuperLooper bioinformatics software were also performed to find superimposing loop structures from the PDB as criteria for reliability. The quality and stability of the model were validated by checking the geometry using PROCHECK (25).

Side chains and loops of the homology model were subjected to conjugate gradient minimization (until converging at a termination gradient of 0.05 kcal/(mol \times Å)) and molecular dynamics simulation (5 ns) by fixing the backbone H-bonds of the TMH. Finally the model was minimized without any constraints. Structure images were produced using PyMOL software (51).









RESULTS

Structural Determinants of Substrate Molecules Determined by Competition with [¹²⁵I]T₃—The only substrates of MCT8 so far identified are iodothyronines (4). A large number of iodothyronines and related molecules are available to probe structural determinants for transport by MCT8. The basic structure of thyroid hormones is the thyronine backbone carrying iodine atoms at one or several of four possible positions (Fig. 2A). The thyroid produces mainly 3,3',5,5'-tetraiodo-L-thyronine (thyroxine, T₄), which can be converted by the action of iodothyronine deiodinases into any iodothyronine (26). Moreover, thyronamines (TAM), decarboxylated iodothyronine derivatives, and iodothyroacetic acids are naturally occurring metabolites and exert biological and pharmacological effects (27, 28). We tested a total number of 23 iodothyronine derivatives for their interference with transport of the paradigmatic MCT8 substrate, T₃. Among L-(iodo)thyronines, only T₄, T₃, rT₃ (3,3',5-triiodothyronine), and 3,3'-diiodothyronine (3,3'-T₂) competed with T₃ for transport (Fig. 2B). We concluded that MCT8 requires for transport at least one iodine atom at the three positions in both aromatic rings.

In addition, L-T₃ transport is inhibited only by L-iodothyronines, whereas their D-isomers had no effect (Fig. 2C). These results support and extend similar studies of rat Mct8 by Friesema *et al.* (4).

FIGURE 1. Alignment of MCT subspecies. The alignment includes members of the human MCTs to extract shared and divergent features of amino acid composition. Especially conserved residues are marked in colors, according to their biophysical properties (blue, positively charged; red, negatively charged; green, hydrophobic; orange, hydrophilic; black, proline), indicating amino acids of functional or structural importance for several or all subspecies. From this alignment, it becomes obvious that the MCTs share high sequence and most likely also structural similarity despite regions of flexibility like the third intracellular loop (ICL3). Asp⁴⁹⁸ of MCT8 is boxed in red and can also be found in MCT10, another T₃-transporting MCT family member. Also boxed are the potential dimensions of the TMHs based on the x-ray structure of an *E. coli* glycerol-3-phosphate transporter, another member of the major facilitator superfamily. We suggest a unifying numbering system for the MCTs indicated by the *italic numbers* above each TMH box. This position identifier scheme uses a highly conserved residue in each transmembrane helix as a common reference for all members of the MCT family. For example, the highly conserved tryptophan in TMH1 is defined as 1.50, and the highly conserved proline from TMH2 is defined as 2.50. The first number is related to the particular helix, and the second number after the dot determines the specific position in relation to the conserved residue. This procedure might be helpful to compare insights from different MCT species. For specific comparison between MCT subtypes, we provide amino acid numbering for each MCT in the *right column*.

Structure-Function Relationships in MCT8



We then asked whether TAM also compete with T_3 for transport by MCT8. In comparison with L-iodothyronines, TAM lack the amino acid carboxyl group and the chiral center.

Inhibition by a 1000-fold excess of any TAM was negligible with the single exception of 3-iodothyronamine (3- T_1 AM), an endogenous metabolite known to exert profound pharmacological effects (27, 29). However, even at 10 μ M, 3- T_1 AM achieved a maximal inhibition of only about 30% of T_3 uptake (Fig. 2D) (30).

Our next question was whether the amino group of the backbone represents an important structural determinant. In contrast to earlier findings with rat Mct8 (4), *N*-acetylation of iodothyronines is apparently tolerated by human MCT8 because NAc- T_3 and NAc- T_4 both exhibited inhibitory effects similar to the non-acetylated compounds (Fig. 2E). TRIAC and 3,3',5,5'-tetraiodo-thyroacetic acid (*TETRAC*) were entirely devoid of inhibitory potential in the competition assay (Fig. 2E).

Our conclusions regarding substrate recognition were supported by the lack of inhibition by 3,5-diiodo-thyropropionic acid (*DITPA*, Fig. 2E), a thyromimetic compound that was used to pharmacologically circumvent the transport deficiency in *Mct8*-deficient mice (31). Unlike the closely related MCT10, MCT8 does not accept aromatic amino acids (Fig. 2F).

Finally, we tested polyphenolic flavonoids F21388 and naringenin for inhibition of T_3 transport. These compounds were previously shown to bind to transthyretin and compete for T_4 binding. Both flavonoids were inactive in this uptake assay in contrast to the known MCT8 inhibitor, bromsulphthalein (*BSP*, Fig. 2G) (4).

Measuring the Uptake of MCT8 Substrates with LC-MS/MS—Competition assays are an easy and common way to determine structural determinants for receptor binding or transport. However, this type of experiment represents an indirect approach. We took advantage of our LC-MS/MS assays for iodothyronines and TAM (17, 18) and directly measured uptake of unlabeled ligands into MCT8-transfected MDCK1 cells. In a first step, we validated the LC-MS/MS method in direct comparison with the established [125 I] T_3 uptake assay (Fig. 3, A and B). The K_m values determined by both methods, 4.7 and 7.5 μ M, are within the range reported for rat, 4–8 μ M (4). We then tested T_3 AM and TRIAC. Even at 50 μ M, both compounds were not transported by MCT8 (Fig. 3C). Thus, the direct assay supports that MCT8 requires the intact L-amino acid backbone for substrate recognition.

Two Charged Amino Acids Are Spatially Located at the Potential Substrate Transport Channel—We were interested in the identification of amino acids in MCT8, which are involved in substrate recognition. Structure-function analysis of the substrate suggested a requirement for both amino and carboxylic functional groups. Therefore, we focused on charged amino acids located in the transmembrane helices. The MCT sequence alignment revealed that all MCTs carry a conserved




FIGURE 3. Comparison of T_3 uptake measurements based on [125 I] T_3 internalization or on LC-MS/MS. A, cell-associated radioactivity depending on substrate (T_3) concentration. Lines represent fitted binding isotherms. All data points were determined in triplicate, and the mean values and S.E. are indicated. The experiments were performed two times with similar results. B, Eadie-Hofstee plot based on data from A. K_m values were not approximated from the plot but were directly calculated from the data using GraphPad software. C, determination of uptake of 50 μ M T_3 , T_3 AM, and TRIAC by wild-type MCT8 by LC-MS/MS. Data are representative of one out of at least two independent T_3 uptake experiments performed in triplicate.

arginine in TMH8 (Arg⁴⁴⁵, position 8.50). In MCT1, the corresponding amino acid (Arg³⁰⁶) is described to be essential for transporter function (23). We built a homology model for MCT8 based on the x-ray structure of GlpT (Fig. 4A). Our model is in a conformation open to the intracellular side (Fig. 4B). In this model, the charged side chain Arg⁴⁴⁵ points into the interior space between the transmembrane helices. Moreover, Arg⁴⁴⁵ protrudes into a solvent-filled cavity, which we presume is the substrate channel (Fig. 4B). This arginine likely interacts within the interior region of the transporter with a negative charge from the substrate. The MCT8 model further suggests a salt bridge between Arg⁴⁴⁵ and Asp⁴⁹⁸ (TMH10). Thus, both charged residues might be involved in essential helix interactions or in substrate recognition.

Mutations in Arg⁴⁴⁵ and Asp⁴⁹⁸ Lead to Total Loss of Transport Activity—To test the significance of the two charged amino acids, Arg⁴⁴⁵ and Asp⁴⁹⁸, for substrate transport, we

FIGURE 2. Competition with [125 I] T_3 in uptake assays reveals essential functional groups in MCT8 substrates. A, chemical structures of iodothyronines. B–G, MDCK1 cells were stably transfected with wild-type MCT8 and empty vector. [125 I]-uptake of cells transfected with pcDNA3.1 was considered as background and subtracted. Uptake without inhibitor was set to 100%. B–G show [125 I] T_3 uptake assays with iodothyronines (B), D- and L-iodothyronines (C), thyronamines (D), iodothyronine derivatives (E), aromatic amino acids (F), and iodothyronine competitors (G). DMSO, dimethyl sulfoxide; DITPA, 3,5-diiodo-thyropropionic acid; TETRAC, 3,3',5,5'-tetraiodo-thyroacetic acid; BSP, bromsulphthalein.




FIGURE 4. Homology model of the human MCT8. *A*, crystal structure of the glycerol-3-phosphate transporter (PDB code 1PW4, white backbone), another member of the major facilitator superfamily, which was used as a structural template. Two arginines and a histidine (blue sticks, dotted circle, GlpT amino acids Arg⁴⁵-TMH1, His¹⁶⁵-TMH5, His¹⁶⁹-TMH5, Arg²⁶⁹-TMH7) are known to be related to glycerol-3-phosphate (G3P) binding, which is mediated by the phosphate moiety of glycerol-3-phosphate (20). This binding site is located in the middle of the transmembrane region of the GlpT and is part of a central cavity that represents the presumed substrate transport channel. *B*, lengths of specific loops and helices may vary in detail between the MCT8 model when compared with the crystal structure of GlpT (*A*), but the overall topology, especially in the transmembrane region, is assumed to be similar. The two charged amino acids Arg⁴⁴⁵ in blue (TMH8) and Asp⁴⁹⁸ in red (TMH10) are located in the central transmembrane part of the MCT8. In the top view with clipped extracellular loops, the arrangement of the helices to each other is visualized and shows TMH8 and TMH10 in close proximity to where these charged residues are located. Both amino acids are in close spatial distance, and they are flanking the potential channel for substrate-transport (light blue circle in the top view). This spatial region superimposes with the known binding region for glycerol-3-phosphate in the GlpT (panel *A*). Therefore, orientations of these residues are predestined for both helix justification and/or substrate binding. Arginine 445 and aspartate 498 are suggested to interact via H-bond (dotted line). Ntt, N-terminal tail; Ctt, C-terminal tail.

replaced both amino acids with alanine, established stable cell clones, and tested their activity. Alanine replacement removes charges while retaining the propensity of a peptide to form helices. Both mutants were expressed at lower levels than wild type but were exposed to the plasma membrane, as shown by surface biotinylation (Fig. 5*A*). Strikingly, both mutants entirely lacked any [¹²⁵I]T₃ uptake activity (Fig. 5*B*). If the functional role of these charged amino acids relied solely on interaction with the amino acid backbone of the iodothyronine substrate, alanine mutants should accept T₃AM or TRIAC at least at high concentrations. We tested this hypothesis directly using the LC-MS/MS assay. Both alanine mutations entirely abrogated transport of T₃, and the mutant MCT8 accepted neither TRIAC nor T₃AM (Fig. 5*C*). This finding is compatible with the assumption that an essential salt bridge between basic Arg⁴⁴⁵ and acidic Asp⁴⁹⁸ may be formed during the transport cycle.

DISCUSSION

As a first step to gain insight into structural features, substrate interaction, and transport mechanism of thyroid hormone transporters, we systematically delineated the conserved structural elements in MCT8 substrates and tried to identify amino acids in MCT8 potentially interacting with substrate. A homology model for MCT8 was built based on the structure of GlpT, a bacterial glycerol-3-phosphate transporter (20). Combining modeling and biochemical approaches, we identified

two essential charged amino acids in TMH8 and TMH10 located in close proximity to the presumed substrate transport channel.

Substrate Determinants Required for Recognition by MCT8—Using 23 iodothyronine and related compounds, we systematically investigated their structure-function relationships to extract key features of MCT8 substrates. Unlike MCT10 (4, 5), MCT8 does not transport aromatic amino acids, suggesting specificity for the thyronine structure. Moreover, human MCT8 is sensitive to the number and distribution of iodine atoms attached to the thyronine backbone. Our data support and extend earlier work done in *Xenopus* oocytes (4) and show that MCT8 substrates have to carry at least an iodine atom in the three positions of both aromatic rings. In addition, an L-amino acid moiety is essential. In contrast to the findings on rat Mct8 expressed in *Xenopus* oocytes (4), human MCT8 expressed in MDCK1 cells tolerated *N*-acetylation of iodothyronines and was not inhibited by D-isomers and TRIAC. Neither naringenin nor F21388 interfered with T₃ transport by MCT8. Hence, MCT8 has higher specificity for iodothyronines than type I-deiodinase (32–34), transthyretin (32), and T₃-receptors (35, 36).

Amino Acids in MCT8 Involved in Both Substrate Recognition and Transport—Our alignment of MCT family amino acid sequences revealed Arg⁴⁴⁵ (position 8.50) as conserved among




FIGURE 5. MCT8 surface translocation and time course of [125 I] T_3 uptake by MCT8 mutants R445A and D498A. A, MDCK1 cells were stably transfected with wild-type MCT8, R445A, D498A, and empty vector. Whole cellular lysates (left panels) were compared by Western blotting for MCT8 with the biotinylated and affinity-purified plasma membrane protein fraction (right panels). Immunoblotting against β -actin was used as loading control (bottom panels). B, for time course experiments, stably transfected MDCK1 cells with MCT8 mutants R445A, D498A, and empty vector were exposed to 10 nM [125 I] T_3 for 1–30 min. The radioactivity associated with empty vector-transfected clones was subtracted as background. Data represent of at least two independent [125 I] T_3 uptake experiments performed in triplicate. C, determination of uptake of 50 μ M T_3 , T_3 AM, and TRIAC by MCT8 mutants R445A and D498A by LC-MS/MS. Data are representative of one out of at least two independent T_3 uptake experiments performed in triplicate. Error bars indicate S.E.

all MCT family proteins (Fig. 1). This high conservation indicates an important and specific function for this amino acid, and indeed, in our homology model, Arg⁴⁴⁵ protrudes into a central cavity in the protein in between the helices (Fig. 4B), which we assume is representing the substrate channel in accordance with the GlpT structure (20). This channel assignment is in agreement with the hypothesis that cavities within membrane gates are encircled by polar amino acids (37). Moreover, this is in agreement with recent results on MCT1, where the involvement of arginine Arg³⁰⁶ (TMH8, position 8.50) for transport activity was found, which corresponds to Arg⁴⁴⁵ (TMH8, position 8.50) in MCT8. In addition, on MCT1, the negatively charged residue Asp³⁰² at the same TMH8 (position 8.46) was also identified to contribute in the transport mechanism (23, 24, 38). Guided by our MCT8 model we found on MCT8 a further charged amino acid, Asp⁴⁹⁸ (TMH10, position 10.49), which may cooperate with Arg⁴⁴⁵ in positioning the invariable L-amino acid moiety of the substrate. Consistent with an assumed substrate interaction is our observation that Asp⁴⁹⁸ is only conserved among MCT8 and MCT10 transporters (Fig. 1), the only MCT family members with known amino acid/iodothyronine substrates. Mutation of either amino acid to alanine entirely abrogates T_3 transport by mutant MCT8, although the mutants were exposed to the plasma membrane.

We speculate that both amino acids may bear a function beyond substrate binding. Indeed, our model suggests a salt bridge between both side chains, which may form at least transiently during the transport cycle. Binding of substrate would cause modification of the charged interaction and in conse-

TABLE 2

Naturally occurring side-chain substitutions at the MCT8

We extracted only those known pathogenic mutations from the literature with single side-chain substitutions (deletions or insertions are not included) because our purpose was to map the positions of such mutations to the three-dimensional MCT8 homology model (Fig. 6) to reveal insights into their spatial neighborhood to residues Arg⁴⁴⁵ and Asp⁴⁹⁸. The mutations are helpful to evaluate function of wild-type amino acids, also with respect to their potential contact partners. Finally the combination of such sequence-structure-(mal)function relationships is a reliable procedure to identify and to describe hot-spots of transport mechanisms. ECL, extracellular loop.

| Structural localization | Substitution | Position | References |
|-------------------------|--------------|----------|--|
| TMH1 | H192R | 1.67 | (39) (Review: Ref. 13) |
| TMH1 | S194F | 1.69 | (8, 14, 42) |
| TMH2 | G221R | 2.38 | (8, 43, 44) |
| TMH2 | A224V/A224T | 2.41 | A224V: Refs. 6, 14, and 42 A224T: Ref. 45 |
| TMH2 | V235M | 2.52 | (8, 14, 42) |
| ECL2/TMH4 | R271H | 4.39 | (14, 42, 45) |
| TMH4 | G282C | 4.50 | (44, 46) |
| TMH5 | P321L | 5.59 | (43) |
| ICL3/TMH7 | G401R | 7.39 | (47) |
| ECL4 | L434W | | (8, 14, 42) |
| TMH8 | R445C | 8.50 | (39) (Review: Ref. 13) |
| TMH8 | D453V | 8.58 | (44) |
| TMH9 | L471P | 9.49 | (6, 14, 42) |
| ICL5 | L512P | | (7, 14) |
| TMH11 | P537L | 11.49 | (44, 48) |
| TMH12 | G558D | 12.54 | (14, 44, 49) |
| TMH12 | G564R | 12.60 | (50) |
| TMH12 | L568P | 12.64 | (8, 14, 42) |

quence break the salt bridge (Arg⁴⁴⁵–Asp⁴⁹⁸), which is possibly specific for the inward facing conformation of MCT8. In this conformation, Arg⁴⁴⁵ establishes simultaneously a H-bond with the backbone of TMH7 and thus constrains a triad of TMH7, TMH8, and TMH10. Destabilization at the interfaces between these helices should facilitate the assumed relative rotation of helices to each other as proposed for GlpT (20). We suggest, therefore, a dual functionality for Arg⁴⁴⁵ and Asp⁴⁹⁸ involving both substrate recognition and the molecular mechanics of transport. We did not create an R445D/D498R double mutant to test the potential salt bridge because our model predicted that arginine at position 498 would block the presumed binding site, whereas an aspartate at position 445 would be too short to reach the solvent-filled channel.

We have mapped known pathogenic missense mutations in MCT8 (Table 2) onto our homology model and observed that some occurred around the region surrounding Arg⁴⁴⁵, Asp⁴⁹⁸, and the presumed substrate channel (Fig. 6), e.g. at Asp⁴⁵³ (TMH8, position 8.58). In the recent review of Friesema *et al.* (13), which was published while our work was in progress, two novel pathogenic mutations were mentioned that are particularly pertinent to our discussion here: R445C and H192R. Both mutations have deleterious effects on T_3 transport in patients (39). According to our structural model, His¹⁹² (TMH1, position 1.66) corresponds to the substrate binding-sensitive Arg⁴⁵ in the GlpT (20, 40). Interestingly, in the crystal structure of the thyroid hormone receptor (PDB code 3GWS (41)), a positively charged amino acid is mandatory and a histidine in a T_3 binding pocket contributes to iodothyronine binding. We therefore conclude that replacement of His¹⁹² with arginine in MCT8 should potentially interfere with binding of substrate. The pathogenic substitution R445C might lead to a loss of ionic interaction(s) consistent with our proposed mechanism for the




FIGURE 6. Mapping of pathogenic side-chain substitutions onto the MCT8 homology model. We conclude from our MCT8 homology model with highlighted amino acid positions (green) of reported pathogenic side-chain substitutions (Table 2) that the spatial region surrounding Asp⁴⁹⁸ and Arg⁴⁴⁵ is characterized by high sensitivity for transport. The close spatial distances to amino acids like Asp⁴⁵³ or His¹⁹², which are also located at the potential transport cavity, are remarkable. However, pathogenic mutations are identified in most of the helices, and some mutations may cause protein-folding defects.

R445A mutant. We conclude that our model can serve as a basis for further investigations into structure-function relationships in MCT8 and may further allow the rational interpretation and prediction of structural changes caused by pathogenic mutations.

Acknowledgments—We thank Anja Fischbach and Antje Kretschmer, Charité, for technical assistance with LC-MS/MS experiments.

REFERENCES

- Hennemann, G., Docter, R., Friesema, E. C., de Jong, M., Krenning, E. P., and Visser, T. J. (2001) *Endocr. Rev.* **22**, 451–476
- Abe, T., Kakyō, M., Sakagami, H., Tokui, T., Nishio, T., Tanemoto, M., Nomura, H., Hebert, S. C., Matsuno, S., Kondo, H., and Yawo, H. (1998) *J. Biol. Chem.* **273**, 22395–22401
- Friesema, E. C., Docter, R., Moerings, E. P., Verrey, F., Krenning, E. P., Hennemann, G., and Visser, T. J. (2001) *Endocrinology* **142**, 4339–4348
- Friesema, E. C., Ganguly, S., Abdalla, A., Manning Fox, J. E., Halestrap, A. P., and Visser, T. J. (2003) *J. Biol. Chem.* **278**, 40128–40135
- Friesema, E. C., Jansen, J., Jachtenberg, J. W., Visser, W. E., Kester, M. H., and Visser, T. J. (2008) *Mol. Endocrinol.* **22**, 1357–1369
- Friesema, E. C., Grueters, A., Biebermann, H., Krude, H., von Moers, A., Reeser, M., Barrett, T. G., Mancilla, E. E., Svensson, J., Kester, M. H., Kuiper, G. G., Balkassmi, S., Uitterlinden, A. G., Köhrle, J., Rodien, P., Halestrap, A. P., and Visser, T. J. (2004) *Lancet* **364**, 1435–1437
- Dumitrescu, A. M., Liao, X. H., Best, T. B., Brockmann, K., and Refetoff, S. (2004) *Am. J. Hum. Genet.* **74**, 168–175
- Schwartz, C. E., May, M. M., Carpenter, N. J., Rogers, R. C., Martin, J., Bialer, M. G., Ward, J., Sanabria, J., Marsa, S., Lewis, J. A., Echeverri, R., Lubbs, H. A., Voeller, K., Simensen, R. J., and Stevenson, R. E. (2005) *Am. J. Hum. Genet.* **77**, 41–53
- Heuer, H., Maier, M. K., Iden, S., Mittag, J., Friesema, E. C., Visser, T. J., and Bauer, K. (2005) *Endocrinology* **146**, 1701–1706

- Dumitrescu, A. M., Liao, X. H., Weiss, R. E., Millen, K., and Refetoff, S. (2006) *Endocrinology* **147**, 4036–4043
- Trajkovic, M., Visser, T. J., Mittag, J., Horn, S., Lukas, J., Darras, V. M., Raivich, G., Bauer, K., and Heuer, H. (2007) *J. Clin. Invest.* **117**, 627–635
- Wirth, E. K., Roth, S., Blechschmidt, C., Hölter, S. M., Becker, L., Racz, I., Zimmer, A., Klopstock, T., Gailus-Durner, V., Fuchs, H., Wurst, W., Naumann, T., Bräuer, A., de Angelis, M. H., Köhrle, J., Grüters, A., and Schweizer, U. (2009) *J. Neurosci.* **29**, 9439–9449
- Friesema, E. C., Visser, W. E., and Visser, T. J. (2010) *Mol. Cell Endocrinol.* **322**, 107–113
- Kinne, A., Roth, S., Biebermann, H., Köhrle, J., Grüters, A., and Schweizer, U. (2009) *J. Mol. Endocrinol.* **43**, 263–271
- Visser, W. E., Philp, N. J., van Dijk, T. B., Klootwijk, W., Friesema, E. C., Jansen, J., Beesley, P. W., Ianculescu, A. G., and Visser, T. J. (2009) *Endocrinology* **150**, 5163–5170
- Biebermann, H., Ambrügger, P., Tarnow, P., von Moers, A., Schweizer, U., and Grueters, A. (2005) *Eur. J. Endocrinol.* **153**, 359–366
- Piehl, S., Heberer, T., Balizs, G., Scanlan, T. S., Smits, R., Koks, B., and Köhrle, J. (2008) *Endocrinology* **149**, 3037–3045
- Piehl, S., Heberer, T., Balizs, G., Scanlan, T. S., and Köhrle, J. (2008) *Rapid Commun. Mass Spectrom.* **22**, 3286–3296
- Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., Lopez, R., Thompson, J. D., Gibson, T. J., and Higgins, D. G. (2007) *Bioinformatics* **23**, 2947–2948
- Huang, Y., Lemieux, M. J., Song, J., Auer, M., and Wang, D. N. (2003) *Science* **301**, 616–620
- Ballesteros, J. A., and Weinstein, H. (1995) *Methods Neurosci.* **25**, 366–428
- Salas-Burgos, A., Iserovich, P., Zuniga, F., Vera, J. C., and Fischbach, J. (2004) *Biophys. J.* **87**, 2990–2999
- Manoharan, C., Wilson, M. C., Sessions, R. B., and Halestrap, A. P. (2006) *Mol. Membr. Biol.* **23**, 486–498
- Wilson, M. C., Meredith, D., Bunnun, C., Sessions, R. B., and Halestrap, A. P. (2009) *J. Biol. Chem.* **284**, 20011–20021
- Laskowski, R. A., Moss, D. S., and Thornton, J. M. (1993) *J. Mol. Biol.* **231**, 1049–1067
- Schweizer, U., Weitzel, J. M., and Schomburg, L. (2008) *Mol. Cell Endocrinol.* **289**, 1–9
- Scanlan, T. S., Suchland, K. L., Hart, M. E., Chiellini, G., Huang, Y., Kruzich, P. J., Frascarelli, S., Crossley, D. A., Bunzow, J. R., Ronca-Testoni, S., Lin, E. T., Hatton, D., Zucchi, R., and Grandy, D. K. (2004) *Nat. Med.* **10**, 638–642
- Wu, S. Y., Green, W. L., Huang, W. S., Hays, M. T., and Chopra, I. J. (2005) *Thyroid* **15**, 943–958
- Scanlan, T. S. (2009) *Endocrinology* **150**, 1108–1111
- Ianculescu, A. G., Giacomini, K. M., and Scanlan, T. S. (2009) *Endocrinology* **150**, 1991–1999
- Di Cosmo, C., Liao, X. H., Dumitrescu, A. M., Weiss, R. E., and Refetoff, S. (2009) *Endocrinology* **150**, 4450–4458
- Köhrle, J., and Hesch, R. D. (1984) *Horm. Metab. Res. Suppl.* **14**, 42–55
- Köhrle, J., Aufmkolk, M., Rokos, H., Hesch, R. D., and Cody, V. (1986) *J. Biol. Chem.* **261**, 11613–11622
- Aufmkolk, M., Köhrle, J., Hesch, R. D., and Cody, V. (1986) *J. Biol. Chem.* **261**, 11623–11630
- Wagner, R. L., Apriletti, J. W., McGrath, M. E., West, B. L., Baxter, J. D., and Fletterick, R. J. (1995) *Nature* **378**, 690–697
- Wagner, R. L., Huber, B. R., Shiao, A. K., Kelly, A., Cunha Lima, S. T., Scanlan, T. S., Apriletti, J. W., Baxter, J. D., West, B. L., and Fletterick, R. J. (2001) *Mol. Endocrinol.* **15**, 398–410
- Hildebrand, P. W., Rother, K., Goede, A., Preissner, R., and Frömmel, C. (2005) *Biophys. J.* **88**, 1970–1977
- Halestrap, A. P., and Meredith, D. (2004) *Pflugers Arch.* **447**, 619–628
- Capri, Y., Friesema, E. C., Touraine, R., Monnier, A., Des Portes, V., De Michele, G., Abramowicz, M., Brady, A., Vaur-Barrière, C., Visser, T. J., and Boespflug-Tanguy, O. (2009) *2nd ELA Research Foundation Congress, Luxembourg, June 26–27, 2009*, ELA Research Foundation, Laxou, France
- Fann, M., Davies, A. H., Varadhachary, A., Kuroda, T., Sevier, C., Tsuch-

- iya, T., and Maloney, P. C. (1998) *J. Membr. Biol.* **164**, 187–195
41. Nascimento, A. S., Dias, S. M., Nunes, F. M., Aparício, R., Ambrosio, A. L., Bleicher, L., Figueira, A. C., Santos, M. A., de Oliveira Neto, M., Fischer, H., Togashi, M., Craievich, A. F., Garratt, R. C., Baxter, J. D., Webb, P., and Polikarpov, I. (2006) *J. Mol. Biol.* **360**, 586–598
 42. Jansen, J., Friesema, E. C., Kester, M. H., Schwartz, C. E., and Visser, T. J. (2008) *Endocrinology* **149**, 2184–2190
 43. Vours-Barrière, C., Deville, M., Sarret, C., Giraud, G., Des Portes, V., Prats-Viñas, J. M., De Michele, G., Dan, B., Brady, A. F., Boespflug-Tanguy, O., and Touraine, R. (2009) *Ann. Neurol.* **65**, 114–118
 44. Friesema, E. C., Kersseboom, S., Visser, W. E., Klootwijk, W., and Visser, T. J. (2009) *34th Annual Meeting of the European Thyroid Association, Lisbon, Portugal, September 5–9*, European Thyroid Association, Regensburg, Germany
 45. Raymond, L., Whibley, A., Price, S., Rosser, E., Rahman, N., Holder, S., Stewart, F., Tarpey, P. R., Futreal, A., Stratton, M., and Gold, I. *European Human Genetics Conference, Barcelona, Spain, May 31–June 3, 2008*, European Society of Human Genetics, Vienna, Austria
 46. Wood, T., Hobson, D., Browning, B., Rogers, C., Skinner, C., Ardinger, C. C., Collins, C. A., Friez, M. J., and Schwartz, C. E. (2008) *European Human Genetics Conference, Barcelona, Spain, May 31–June 3, 2008*, European Society of Human Genetics, Vienna, Austria
 47. Namba, N., Mohri, I., Abe, S., Kitaoka, T., Miura, K., Hirai, H., Kitai, Y., Sakai, N., Taniike, M., and Ozono, K. (2009) 91st Annual Meeting of The Endocrine Society, Washington, D.C., June 10–13, 2009, The Endocrine Society, Chevy Chase, MD
 48. Papadimitriou, A., Dumitrescu, A. M., Papavasiliou, A., Fretzayas, A., Nicolaidou, P., and Refetoff, S. (2008) *Pediatrics* **121**, e199–e202
 49. Frints, S. G., Lenzner, S., Bauters, M., Jensen, L. R., Van Esch, H., des Portes, V., Moog, U., Macville, M. V., van Roozendaal, K., Schrandt-Stumpel, C. T., Tzschach, A., Marynen, P., Fryns, J. P., Hamel, B., van Bokhoven, H., Chelly, J., Beldjord, C., Turner, G., Gecz, J., Moraine, C., Raynaud, M., Ropers, H. H., Froyen, G., and Kuss, A. W. (2008) *Eur. J. Hum. Genet.* **16**, 1029–1037
 50. Visser, W. E., Jansen, J., Friesema, E. C., Kester, M. H., Mancilla, E., Lundgren, J., van der Knaap, M. S., Lunsing, R. J., Brouwer, O. F., and Visser, T. J. (2009) *Hum. Mutat.* **30**, 29–38
 51. DeLano, W. L. (2002) *The PyMOL Molecular Graphics System, version 0.99*, DeLano Scientific LLC, San Carlos, CA